Skip to main content

Table 4 Intragroup and intergroup comparison of the 7 dimensions and the total score of the OHIP-14

From: Mini Hyrax vs Hyrax expanders in the rapid palatal expansion in adolescents with posterior crossbite: a randomized controlled clinical trial

Dimensions OHIP 14

T0 Mean (SD)

T1 Mean (SD)

T2 Mean (SD)

Statistical difference T0-T1-T2

T0 Mean (SD)

T1 Mean (SD)

T2 Mean (SD)

Statistical difference T0–T1–T2

Statistical difference

Coef. (95% CI)

p value

Statistical difference

Coef. (95% CI)

p value

Mini Hyrax

   

Hyrax

   

Mini Hyrax x Hyrax

(T1 × T0)

Mini Hyrax x Hyrax

(T2 × T0)

FL

0.73 (1.22)a

2.53 (2.06)b

1.93 (1.28)ab

0.031*

0.73 (1.10)a

2.60 (1.18)b

2.13 (1.88)ab

0.010*

0.06 (− 1.21–1.34) 0.916**

0.20 (− 1.02–1.42)

0.740***

FD

2.47 (1.80)a

3.93 (2.15)b

2.87 (2.03)ab

0.048*

1.80 (1.14)a

3.87 (1.76)b

2.40 (1.50)a

0.001*

0.13 (− 1.36–1.63)

0.859**

− 0.50 (− 1.90–0.88)

0.463***

PD

3.87 (2.41)a

2.40 (2.61)a

1.60 (2.26)a

0.088*

2.53 (2.16)a

2.47 (2.13)a

2.00 (1.55)a

0.646*

0.26 (− 1.61–2.14)

0.774**

0.32 (− 1.22–1.68)

0.673***

FD

0.73 (1.16)a

0.87 (1.06)a

0.47 (0.83)a

0.391*

0.47 (0.74)a

1.93 (2.05)a

1.00 (1.36)a

0.065*

1.07 (− 0.18–2.33)

0.091**

0.59 (− 0.26–1.44)

0.167***

PD

3.13 (2.29)a

2.20 (1.74)a

1.53 (1.76)a

0.196*

1.27 (1.38)a

1.47 (1.76)a

0.67 (0.72)a

0.051*

− 0.94 (− 2.43–0.54)

0.206**

− 1.15 (− 2.28–0.03)

0.052***

SD

1.60 (1.84)ab

1.20 (1.74)a

0.53 (0.99)b

0.038*

0.60 (1.12)ab

0.67 (1.17)a

0.13 (0.35)b

0.009*

− 0.31 (− 1.48–0.85)

0.583**

− 0.32 (− 0.91–0.26)

0.272***

HC

0.80 (1.14)a

0.40 (0.82)ab

0.00 (0.00)b

0.030*

0.40 (0.73)a

0.40 (0.82)ab

0.07 (0.25)b

0.049*

0.02 (− 0.61–0.67)

0.930**

0.06 (− 0.08–0.20)

0.390***

SCO

13.33 (8.04)ab

13.53 (7.12)a

8.93 (5.67)b

0.026*

7.80 (6.80)ab

13.40 (8.49)a

8.33 (5.86)b

0.040*

− 0.08 (− 6.49–6.32)

0.978**

− 0.70 (− 5.41–4.01)

0.762***

  1. T0 pretreatment, T1 14th day of the appliance activation, T2 after 6 months retention period, SD standard deviation, FL functional limitation, FD physical discomfort, PD psychological discomfort, FD physical disability, PD psychological disability, SD social disability, HC handicaps, SCO total score
  2. *ANOVA test for repeated measures, Level of significance p < 0.05
  3. For comparison of pairs T0 X T1, T0 X T2, T1 X T2 in Mini-Hyrax group and Hyrax group, paired t test was employed. Different letters indicate significant difference. Bonferroni correction. Level of significance p < 0.016
  4. Coef coefficient
  5. **Regression analysis assessing differences between Mini-Hyrax and Hyrax groups of the OHIP-14 scores at T1, controlling for the OHIP-14 scores at T0. Level of significance p < 0.05
  6. ***Regression analysis assessing differences between Mini-Hyrax and Hyrax groups of the OHIP-14 scores at T2, controlling for the OHIP-14 scores at T0. Level of significance p < 0.05